LABORATORY CORP OF AMERICA HOLDINGS

Form 8-K March 01, 2006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 23, 2006
(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact Name of Registrant as Specified in its Charter)

DELAWARE	1-11353	13-3757370
(State or other jurisdiction of Incorporation)	(Commission File Number)	`
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA	27215	336-229-1127
(Address of principal executive offices)	(Zip Code)	(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Information in Report

ITEM 1.01. Entry into a Material Definitive Agreement

On February 23, 2006, the Board of Directors of Laboratory Corporation of America Holdings (the Company), after discussion and input from outside compensation consultants, accepted and ratified the conclusions and recommendations of the Company s Compensation Committee (Committee) with respect to the following actions:

2005 Management Incentive Bonus. The Committee authorized the payment of the annual incentive awards with respect to the year ended December 31, 2005. These awards were made pursuant to the Company s Management Incentive Bonus Plan, as amended and restated (the MIB Plan). As in prior years, the Committee used the following factors for the 2005 MIB Plan: Corporate EBITDA, expense control, revenue growth, DSO goal (days), and EPS. A customer retention percentage and goal was established for the 2005 MIB Plan year. The table below sets forth the cash payments to the following executive officers with respect to their earned bonus for 2005.

NAME TITLE		MIB PAYMENT		
Thomas P. Mac Mahon	Chairman and Chief Executive Officer	\$1,322,113		
	Executive Vice President, Strategic Planning and			
Richard L. Novak	Corporate Development	542,315		
	Executive Vice President, Chief Legal Officer and			
Bradford T. Smith	Secretary	444,059		
	Executive Vice President, Chief Scientific Officer and			
Myla P. Lai-Goldman	Medical Doctor	302,706		
David P. King	Executive Vice President and Chief Operating Officer	216,697		
2006 Base Salaries. The 2006 bas	e salary levels were effective January 1, 2006, for David P. King and William	m B. Hayes, and are effective		
March 1, 2006, for the other execu	tive officers listed in the table below.			

NAME	TITLE	200	5 BASE	200	06 BASE
Thomas P. Mac Mahon	Chairman and Chief Executive Officer	\$	937,125	\$	1,000,000
David P. King	Executive Vice President and Chief Operating Officer		341,000		450,000
William B. Hayes	Executive Vice President, Chief Financial Officer and Treasurer		250,000		350,000
Benjamin R. Miller	Executive Vice President, Oncology Products and Services		250,000		275,000

2006 Management Incentive Bonus. In connection with the Company's MIB Plan, the Committee used the following factors to set the guidelines for the 2006 MIB Plan: Corporate EBITDA, expense control, revenue growth, bad debt percentage, and EPS. The table below sets forth the 2006 bonus potential for the following executive officers for 2006.

NAME	NAME TITLE	
Thomas P. Mac Mahon	Chairman and Chief Executive Officer	\$ 1,500,000
Richard L. Novak	Executive Vice President, Strategic Planning and Corporate Development	660,000
Bradford T. Smith	Executive Vice President, Chief Legal Officer and Secretary	456,435
Myla P. Lai-Goldman	Executive Vice President, Chief Scientific Officer and Medical Doctor	279,869
David P. King	Executive Vice President and Chief Operating Officer	562,500

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<u>Laboratory Corporation of America Holdings</u> (Registrant)

Date: March 1, 2006 By: /s/Bradford T. Smith

Bradford T. Smith, Executive Vice

President and Secretary